Omeros (OMER) Stock: Buy, Sell, or Hold?
OMER - Omeros Corporation
$18.28
-0.31 (-1.67%)
âŧ
5d:
-4.34%
30d:
+33.33%
90d:
+79.57%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When OMER Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: OMER is fairly priced but lacks strong directional signals. At -38.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: OMER is fairly priced but lacks strong directional signals. At -38.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$55.74
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$34.61
47.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: OMER is currently trading at $18.28, which is considered slightly high relative to its 30-day fair value range of $14.51 to $19.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 16.0) compared to its historical average (68.8). Remarkably, the market is currently pricing in an annual earnings decline of 38.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OMER is in a strong uptrend. The price is currently testing key support at $18.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OMER scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.00 (+80.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OMER is in a strong uptrend. The price is currently testing key support at $18.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: OMER scores 21/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.00 (+80.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$14.51 -
$19.56
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
Protect Your Profits
Holding OMER? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (21/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 80.5% below Wall St target ($33.00)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.51 -
$19.56
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$18.01
Resistance Level
$19.55
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.97
Wall Street Target
$33.00
(+80.5%)
Revenue Growth (YoY)
14.9%
Profit Margin
324.9%
Valuation Discount vs History
-38.6% cheaper
PE vs Historical
16.0 vs 68.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-38.6%
(market-implied from PE analysis)
1-Year Target
$16.45
(-10%)
2-Year Target
$14.81
(-19%)
3-Year Target
$13.33
(-27%)
3-Yr Target (if PE normalizes)
(PE: 16â69)
$57.43
(+214%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 73.5%)
$77.94
(+326%)
Base:
(SPY PE: 16.0, Growth: 73.5%)
$61.70
(+238%)
Bear:
(PE: 13.6, Growth: 73.5%)
$52.44
(+187%)
đ
Valuation based on Current Earnings
Trailing PE: 11.77 | Current EPS (TTM): $1.58
Bull Case
$14.82
(-19%)
Analyst growth -27.5%, PE expands to 12.9
Base Case
$13.47
(-26%)
Market implied -27.5%, PE stable at 11.8
Bear Case
$12.64
(-31%)
Severe decline -20.0%, PE contracts to 10.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.0 to 68.8
Stabilization Target:
$78.78
(+330.9%)
PE Expansion Potential:
+330.9%
Share & Embed Analysis
Last updated: September 12, 2026 11:13 PM ET
Data refreshes hourly during market hours. Next update: 12:13 AM
Data refreshes hourly during market hours. Next update: 12:13 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OMER showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
Advanced OMER Option Strategies
Professional options setups generated by AI based on today's OMER price and gamma walls.
